HIRO-CAPITAL
8.4.2021 07:02:08 CEST | Business Wire | Press release
Hiro Capital – the London / Luxembourg VC fund investing across Games, Esports, Streaming and Digital Sports – has further strengthened its portfolio by leading a $2.3m investment in PlayerData .
Edinburgh, UK-based PlayerData’s mission is to transform the way grass-roots and professional sports teams train, using software, analytics, gamification and wearable technology.
- In its first year live, PlayerData has already captured more than 10,000 team sessions and >50 million meters of athlete play in UK grass-roots Soccer and Rugby, and these KPIs are strongly accelerating.
- The $2.3m raise will be used to supercharge PlayerData’s growth across multiple sports and to expand internationally.
PlayerData combines frictionless ease-of-use with sports-science Machine Learning.
- PlayerData drives powerful team network effects, with each club using PlayerData bringing 5 more clubs onto the platform.
- PlayerData’s AI algorithms predict player injuries before they happen and its tools allow coaches to replay key moments from the game, modelling different outcomes based on player positioning.
This announcement marks Hiro Capital’s 12th investment in 2020/21 and its 4th in Gamified Fitness and Sports tech. PlayerData joins fellow Digital Sports startups FitXR (London), Zwift (California/London) and NURVV (London) in the Hiro Capital portfolio, alongside eight Games studios and Games technology firms across the US, Europe and the UK.
The rise of Digital Sports and Connected Fitness
Digital Sports and Connected Fitness are star growth sectors of 2020/21. Global Connected Fitness revenues grew 30% in 2020 and Health and Fitness app downloads grew +47% YoY to c.700m, accelerated by a global focus on health and wellbeing during lockdowns.
Unicorn scale stars of the sector include Peloton, Tonal, Mirror and Hiro’s portfolio investment, Zwift, as well as major strategic Sports and Wellness segments within Apple (Watch 6 and Fitness+), Google (Fitbit), Nike (Nike App), and others. In Digital Sports, alongside Zwift, Hiro’s lead investments powered ahead:
FitXR: The leading VR Fitness App & Service
- FitXR has made extraordinary progress since Hiro invested, with revenues up 10x over the last 2 quarters and now >$1m per month;
- Described by Oculus VP Content Mike Verdu as having “incredible traction” and “one of the highest retention rates on the [Oculus VR] platform”*, and name-checked by Mark Zuckerberg** on his recent “The Information” podcast on VR/AR and the Metaverse.
*”From Bear to Bull: How Oculus Quest 2 is Changing the Game for VR”, Mike Verdu, VP Content, Oculus 2nd Feb 2020
**Mark Zuckerberg on Mind Reading, Apple, and the Race to Mainstream VR, March 8th 2021
NURVV: Patented Smart Running insole and Biomechanical Data Leader
- Since launch in mid-2020, NURVV Run has generated data on >100 million foot-strikes from >125,000km run by athletes around the world, building what is already the world’s largest database of detailed running foot technique;
- Olympic gold-medallist and world-record holder Dame Kelly Holmes has joined NURVV as global brand ambassador; USA Olympian Jared Ward, UK elite coach Harry Jameson, the Financial Times, WIRED, Runner’s World and CNET have all recommended NURVV;
- With iOS, Android, Garmin ConnectIQ, Strava and Apple Watch integrations live, the company is leading running innovation with unique features such as Pace Coach, Footstrike Workout and Running Health score.
- "Knowledge really is power and in this respect NURVV Run is a game changer" said Dame Kelly Holmes.
PlayerData: AI Driven Team Performance
Roy Hotrabhvanon, cofounder & CEO of PlayerData, is a former international archer who narrowly missed out on selection for the Rio Olympics in 2016 for the Thailand national team. Hayden Ball, cofounder and CTO is a CompSci expert in firmware and cloud infrastructure who designed, built, and launched a distributed SaaS solution for the Edinburgh Fringe.
On the Hiro investment, Roy said - “Our mission is to bring fine grained data and insight to clubs across team sports, helping them supercharge their game-making, improve player performance, and avoid injury. We leverage our platform and big data to generate biometric insights applicable at any level - from grassroots to the Premier League. Due to the team network effect, the PlayerData community is fast-growing across the U.K. and overseas. Our ultimate goal is to implement cutting-edge insights from pioneering wearables that are applicable to any team in any discipline at any level. Hiro Capital as an investment partner, shares this commitment to our mission. It’s great to have Cherry, Luke and Ian’s belief, counsel and expertise to help us further our vision. ”
Cherry Freeman, co-founding Partner at Hiro says: “PlayerData ticks all of our key boxes: a huge TAM with over 3m grass-roots clubs; a deep moat built on shared player data, machine learning and highly actionable predictive algorithms; compelling customer network effects; and a really impressive yet humble founding team. We are delighted to be leading this investment round in this exciting DSports innovator ”
Luke Alvarez, Managing Partner at Hiro says: “In a year when lockdown accelerated digital adoption and kept us all out of the gym, companies like Nurvv, FitXR, Zwift and Peloton helped people stay fit, healthy, and biomechanically self-aware. 2020 super-charged connected fitness and PlayerData is our latest exciting investment in this accelerating macro trend .”
About Hiro Capital
Hiro Capital is a London / Luxembourg technology Venture Capital fund which invests in UK, US and European innovators in Games, Metaverse Technology, Esports and Digital Fitness. Hiro Capital generally invests at the post-seed Series A and B stages. We invest both in front-end Content creators in Games, Esports and Digital Sports and in deep tech Metaverse applications of Cloud, Mobile, Streaming, Big Data, AI, Wearables, AR and VR technologies.
We back experienced entrepreneurial teams, building innovative technologies and content with a strongly differentiated proposition and with the scaling opportunity to become very large.
We are Games, Esports and Sports investors who are also Games, Esports and Sports entrepreneurs. We are entrepreneurs who back entrepreneurs. Our core belief is that Games, Esports and Digital Sports will be a central pillar of Entertainment, Economic and Social Life in the mid 21st century. We invest in the innovators who are building that future.
The fund was founded by Luke Alvarez (Managing Partner) the former co-founding CEO & President of Nasdaq-listed, Inspired Entertainment; Ian Livingstone, OBE, CBE (Partner), the former chairman of Tomb Raider publisher Eidos plc, co-founder of Games Workshop and author of the Fighting Fantasy gamebook series; and Cherry Freeman (Partner), the co-founder of global community and e-commerce brand LoveCrafts. https://hiro.capital/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005773/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom